Researchers have demonstrated that treatment with sodium thiosulfate significantly reduced cisplatin-induced hearing difficulties in children and adolescents with cancer.
Browsing: Phase III
Niraparib, a highly selective PARP inhibitor, has been demonstrated to significantly improve progression-free survival in patients with platinum-sensitive recurrent ovarian cancer, regardless of BRCA-mutation status.
ESMO16: Atezolizumab significantly improves lung cancer survival vs standard chemotherapy in Phase III trial
A collaborative study presented at ESMO16 suggests that the PD-L1 inhibitor atezolizumab reduces the risk of death in patients with advanced non-small-cell lung cancer.
Results from the ongoing VIVIANE study find the human papillomavirus 16/18 vaccine is effective in protecting women over the age of 25 years against infection.
Phase III data indicate that regorafenib increases survival rates in patients with hepatocellular carcinoma, highlighting potential as a second-line therapy.
Newly presented Phase III data have demonstrated the ability of a novel monoclonal antibody to have a significant impact on symptoms and outcomes in advanced colorectal cancer, while being well-tolerated.
Randomized trials often require involvement of hundreds of patients to identify clinically meaningful differences – in terms or rare cancer, read as Ian Olver debates whether clinical trials should be approached differently in this opinion piece from Future Oncology.
The results of a Phase III trial have indicated that the addition of a second autologous stem cell transplant to therapy for children with neuroblastoma could improve survival.
Infographic: Pixantrone–rituximab versus gemcitabine–rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma
View our exclusive infographic depicting the rationale and design of the ongoing Phase III PIX306 study, which is evaluating the efficacy of pixantrone and rituximab vs gemcitabine and rituximab in patients with diffuse large B-cell lymphoma or follicular grade 3 lymphoma.
Pixantrone–rituximab versus gemcitabine–rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma
This Clinical Trial Protocol article from Future Oncology presents the rationale and design of an ongoing Phase III trial evaluating the efficacy of pixantrone & rituximab versus gemcitabine & rituximab in patients with diffuse large B-cell lymphoma.